Kathryn CorzoHead of Development Oncology Cell Therapies at Takeda
Based at Takeda’s Cambridge Massachusetts R&D campus, Kathryn is responsible for leading and overseeing development of Takeda’s Oncology cell therapy pipeline including collaborations with academic and biotech innovation partnerships. Previously, Kathryn was at Sanofi Genzyme where as Vice President R&D Global Program Head for Myeloma she is credited for leading multi-functional teams advancing novel therapeutic candidates from early proof of concept (POC) through pivotal trials, worldwide regulatory approvals, indication expansion and product launch. Before Sanofi she successfully built a two decades career within biopharma at Roche, Eli Lilly and Syndax taking on leadership roles in R&D operations, global clinical development, medical affairs, business development, market access and brand management across multiple platforms and oncology indications. Kathryn has worked to improve outcomes for cancer patients and played an integral role in the development of 12 innovative investigational drugs and 5 commercial products.
Kathryn holds an MBA from Massachusetts Institute of Technology Sloan School of Management and a BS degree in Pharmacy from Massachusetts College of Pharmacy.